Biotech Rally Poised to Continue as Innovation, Obesity Market, and M&A Drive Sector Momentum
核心洞察
Biotech stocks have surged over the past year, with the NYSE Arca Biotechnology Index and Nasdaq Biotechnology Index returning more than 56%, outpacing the Nasdaq 100's 29% gain.
Goldman Sachs (搜索) analysts point to strong fundamentals driven by innovation in cardiovascular disease, cancer, and Alzheimer's, with key data readouts expected in the second half of the year.
The obesity drug market is projected to reach $114 billion globally by 2030, with oral medications expected to comprise 40% of the market and Medicare coverage unlocking further growth.
Biotechnology stocks have quietly built one of the most compelling rallies on Wall Street over the past year, outpacing even the technology sector, and industry analysts at Goldman Sachs (搜索) say the momentum is far from over. Two key benchmarks — the NYSE Arca Biotechnology Index and the Nasdaq Biotechnology Index — returned more than 56% in the 12 months through July 7, topping the Nasdaq 100's 29% upswing over the same period.
"Many large-cap biopharma companies have handily outperformed leading tech names this year," said Asad Haider, head of US healthcare and pharmaceuticals at Goldman Sachs (搜索) Research. "One thing I think investors should appreciate is the product cycle momentum in healthcare. Innovation is going to get rewarded."
The rally has been broad-based. The State Street SPDR S&P Biotech ETF (XBI) surged nearly 80% over the past 12 months, while the iShares Biotechnology ETF (IBB) gained more than 40%, compared with the S&P 500's roughly 19% gain. The XBI alone is up more than 25% year-to-date, benefiting from its equal-weighting structure that captures broad improvement across the sector.
Innovation Pipeline Fuels Optimism
Salveen Richter, head of US healthcare and biotechnology at Goldman Sachs (搜索) Research, emphasized that the fundamentals underpinning biotech remain robust. "The fundamentals of biotech are extremely strong," Richter said, pointing to key data expected in areas such as cardiovascular disease, cancer, and Alzheimer's disease from the second half of the year onward.
That sentiment was echoed at Goldman Sachs (搜索)' 47th Annual Global Healthcare Conference in Miami in June, where the tone among industry executives was markedly bullish compared with the guarded mood at the prior year's gathering, which had been shaped by US trade policy adjustments.
M&A Appetite Builds as Patents Expire
A major driver of continued optimism is the expectation of increased merger and acquisition activity. Large pharmaceutical companies are confronting a wave of patent expirations and need to replenish their pipelines.
"There is an appetite for M&A, and the large-cap biopharma companies leaned into this notion of wanting to do more deals," Haider said. "That's a show of confidence."
Richter noted that small- and mid-cap biotechnology stocks stand to benefit most directly from this trend. "Large biopharma firms are constantly searching for innovation to fill their pipelines," she said. "And they also have to address losses of exclusivity playing out in their portfolio." Promising areas for potential M&A include oncology, immunology, neuroscience, and cardiometabolic health, particularly given the intense focus on obesity.
Evan McCulloch, lead portfolio manager of the Franklin Biotechnology Discovery Fund (FBDIX), which has ranked in the top-performing quartile of funds in its category on a 1-, 3-, 5-, and 10-year basis according to Morningstar, also sees M&A as a critical catalyst. "M&A is always a very important driver for us, and we do think it will continue," McCulloch said.
Obesity Drug Market: A $114 Billion Opportunity
The obesity drug market is emerging as one of the most transformative opportunities in healthcare. Goldman Sachs (搜索) Research recently increased its 2030 forecast for global sales of obesity drugs by 15%, to $114 billion, with oral medications expected to comprise 40% of the worldwide market.
"What's striking about the evolution of the obesity marketplace is that it's driven by consumers as well as medical patients," Haider said. "It is behaving like no other pharmaceutical market we have ever seen."
The market spans a wide spectrum: from severely obese patients requiring bariatric surgery and regular injectable medications at the higher-cost end, to consumers seeking modest weight loss or microdosing regimens who are well-suited for more affordable oral options. "Patients are going to opt for what appeals to them most in this consumer market," Richter said. "That means patients will take a weekly oral or even go the monthly to quarterly injectable route in the context of actual weight loss and tolerability dynamics."
Additional demand catalysts are emerging. As of July 1, Medicare patients became eligible to apply for coverage of obesity drugs in both oral and injectable forms. Goldman Sachs (搜索) Research also raised its estimate for overseas sales by 4 percentage points to 42% of the global market. "We believe the size of the weight-loss market outside the US has been underestimated," Haider said.
China and AI Reshape the Landscape
Beyond specific therapeutic areas, two structural forces are reshaping the pharmaceutical sector. China has become an important source of innovation and a sought-after venue for clinical trials, with its biopharma industry emerging as a notable producer of leading cancer therapies. Meanwhile, artificial intelligence promises fundamental changes to healthcare, with one CEO at the Goldman Sachs (搜索) conference sharing how AI applications are already enabling significant cost reductions and contributing to earnings performance.
Clinical Breakthroughs in Oncology
On the clinical front, Revolution Medicines has drawn significant investor attention after its drug daraxonrasib, a daily pill for pancreatic cancer (搜索), succeeded in a Phase 3 trial. The drug doubled the length of survival and lowered the risk of death by 60% compared to conventional chemotherapy. The company is now preparing for FDA approval.
"I can't go a day without someone asking me about that," said McCulloch, whose fund held Revolution Medicines as its seventh-largest position at 3.1% of assets as of June 30. "It's practically a shoe-in for approval."
Risks and Volatility Considerations
Despite the broadly positive outlook, analysts caution that risks remain. Matt Bartolini, global head of research strategists at State Street Investment Management, warned that the XBI carries a one-year standard deviation of 19%, compared with approximately 13% for the S&P 500 and 16% for the broad healthcare sector, signaling potential for continued volatility. Uncertainty around Federal Reserve interest rate policy also looms.
Still, the overall assessment from Goldman Sachs (搜索) is constructive. "This year, we asked all our companies, 'Are there any banana peels in the external environment that you are keeping your eyes out for and that investors should be aware of?'" Haider said. "Their answers were constructive. And there is a tremendous amount of M&A balance sheet capacity out there among the large-cap biopharma companies."
Richter summed up the outlook succinctly: "M&A needs to happen in this space, and it will happen in this space."